Contact allergy to polyhexamethylene biguanide (polyaminopropyl biguanide).


Journal

Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950

Informations de publication

Date de publication:
May 2021
Historique:
revised: 15 10 2020
received: 14 09 2020
accepted: 19 10 2020
pubmed: 25 10 2020
medline: 4 11 2021
entrez: 24 10 2020
Statut: ppublish

Résumé

Polyaminopropyl biguanide (INCI name) and polyhexamethylene biguanide (PHMB) are polymeric biguanides. PHMB is a broad-spectrum antimicrobial substance used as a preservative in many products. Due to our limited knowledge on PHMB contact allergy frequency and the fact that cases of allergic contact dermatitis to PHMB might be missed, we have included PHMB as a screening allergen since 2016. To report the prevalence of positive patch test reactions to PHMB as a screening allergen in patients with suspected allergic contact dermatitis. A retrospective analysis of 1760 patch tested patients from July 2016 to December 2018 was performed. Polyaminopropyl biguanide 2.0% aqua was included in the extended Malmö baseline series during the study period. Of all patients, 1204 (68.4%) were female. Positive patch test reactions were reported in 19 patients (1.1%). The most common sites of lesions were face, head, and neck (52.6%). There was a significant correlation between concomitant reactions to PHMB and other cosmetic-related allergens. The prevalence of positive reactions to PHMB was higher than that previously reported. Patch testing with PHMB should be performed in patients with dermatitis who have lesions on the face, head, and neck.

Sections du résumé

BACKGROUND BACKGROUND
Polyaminopropyl biguanide (INCI name) and polyhexamethylene biguanide (PHMB) are polymeric biguanides. PHMB is a broad-spectrum antimicrobial substance used as a preservative in many products. Due to our limited knowledge on PHMB contact allergy frequency and the fact that cases of allergic contact dermatitis to PHMB might be missed, we have included PHMB as a screening allergen since 2016.
OBJECTIVE OBJECTIVE
To report the prevalence of positive patch test reactions to PHMB as a screening allergen in patients with suspected allergic contact dermatitis.
METHODS METHODS
A retrospective analysis of 1760 patch tested patients from July 2016 to December 2018 was performed. Polyaminopropyl biguanide 2.0% aqua was included in the extended Malmö baseline series during the study period.
RESULTS RESULTS
Of all patients, 1204 (68.4%) were female. Positive patch test reactions were reported in 19 patients (1.1%). The most common sites of lesions were face, head, and neck (52.6%). There was a significant correlation between concomitant reactions to PHMB and other cosmetic-related allergens.
CONCLUSION CONCLUSIONS
The prevalence of positive reactions to PHMB was higher than that previously reported. Patch testing with PHMB should be performed in patients with dermatitis who have lesions on the face, head, and neck.

Identifiants

pubmed: 33098110
doi: 10.1111/cod.13728
pmc: PMC8048451
doi:

Substances chimiques

Biguanides 0
Cosmetics 0
Preservatives, Pharmaceutical 0
polyaminopropylbiguanide 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

326-331

Informations de copyright

© 2020 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.

Références

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1516-1525
pubmed: 28627111
Contact Dermatitis. 2014 Nov;71(5):307-9
pubmed: 25345793
Contact Dermatitis. 2021 May;84(5):326-331
pubmed: 33098110
Contact Dermatitis. 2016 Jan;74(1):53-5
pubmed: 26690278
Contact Dermatitis. 2014 Nov;71(5):273-9
pubmed: 25141986
Contact Dermatitis. 1986 Feb;14(2):119-20
pubmed: 3709149
Eur J Dermatol. 2018 Oct 1;28(5):668-676
pubmed: 30530435
J Cosmet Sci. 2015 Sep-Oct;66(5):313-23
pubmed: 26753435
Int Arch Allergy Immunol. 2017;173(4):233-236
pubmed: 28848174
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):333-339
pubmed: 31419348
Acta Derm Venereol. 2015 Jul;95(6):717-9
pubmed: 25474255
Dermatitis. 2015 Sep-Oct;26(5):230-4
pubmed: 26367206
Contact Dermatitis. 2014 May;70(5):323-5
pubmed: 24731091
Contact Dermatitis. 2017 Jun;76(6):373-376
pubmed: 28497633
Contact Dermatitis. 2007 Apr;56(4):235-9
pubmed: 17343627
Contact Dermatitis. 2019 Feb;80(2):110-113
pubmed: 30426516
J Med Microbiol. 2016 Aug;65(8):867-876
pubmed: 27302218
Contact Dermatitis. 2000 May;42(5):302-3
pubmed: 10789863
J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2064-5
pubmed: 25065650
Contact Dermatitis. 2017 Dec;77(6):421-422
pubmed: 29164688

Auteurs

Thanisorn Sukakul (T)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Jakob Dahlin (J)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Ann Pontén (A)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Annarita Antelmi (A)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Magnus Bruze (M)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Nils Hamnerius (N)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Inese Hauksson (I)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Marléne Isaksson (M)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Tina Lejding (T)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Cecilia Svedman (C)

Lund University, Department of Occupational and Environmental Dermatology, Skåne University Hospital, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH